High Efficacy Halts ViiV HIV Prevention Study Early

ViiV Hopes Faster Cabotegravir Approval Will Be The Result

HIV_Blood_Test
HPTN 083 compared injectable long-acting cabotegravir with daily Truvada pills. • Source: Shutterstock

More from Clinical Trials

More from R&D